Market Overview

UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Related ALKS
Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years
Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating

Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00.

Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We added a key new pipeline drug (3831 for schizophrenia) due to new disclosure Jan. 4, and we have greater conviction that Alkermes can develop new drugs to offset patent expirations in 2019 and beyond."

Alkermes plc closed at $21.61 on Wednesday.

Latest Ratings for ALKS

Nov 2015Leerink SwannMaintainsOutperform
Oct 2015BarclaysMaintainsOverweight
Oct 2015BarclaysMaintainsOverweight

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (ALKS)

Get Benzinga's Newsletters